Macrolide and linezolid susceptibility testing for Mycobacterium intracellulare isolates
- Author:
- No author available
- Journal Title:
- Chinese Journal of Tuberculosis and Respiratory Diseases
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1001-0939.2014.04.009
- Key Word:
- 分枝杆菌,鸟复合;微生物敏感性试验;Mycobacterium avium complex;Microbial sensitivity tests
Abstract： Objective To investigate the susceptibility of Mycobacterium intracellulare isolates to clarithromycin,azithromycin and linezolid,and therefore to explore the possibility of using these drugs to treat Mycobacterium intracellulare diseases.Methods The minimal inhibitory concentrations (MICs) of the 3 antibiotics against 76 Mycobacterium intracellulare isolates were determined by using microplate alamar blue assay (MABA).Results The MIC90 of clarithromycin against Mycobacterium intracellulare isolates was 2 mg/L.The proportion of susceptible,intermediate and resistant isolates to clarithromycin was 93.4％ (71/76),0.0％ (0/76) and 6.6％ (5/76),respectively.The MIC90 of azithromycin against the isolates was 32 mg/L.The proportion of susceptible,intermediate and resistant isolates to azithromycin was 94.7％ (72/76),0.0％ (0/76) and 5.3％ (4/76),respectively.The MIC90 of linezolid was 64 mg/L.The proportion of susceptible,intermediate and resistant isolates to linezolid was 32.9％ (25/76),22.4％ (17/ 76) and 44.7％ (34/76),respectively.Among the 5 isolates resistant to clarithromycin,4 were resistant to azithromycin,and 2 were resistant to linezolid.Conclusions Most of the Mycobacterium intracellulare isolates were sensitive to clarithromycin.High cross-resistance between clarithromycin and azithromycin was present,but some clarithromycin-resistant isolates were sensitive to linezolid.
- [1]中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会.非结核分枝杆菌病诊断与治疗专家共识[J].2012,(8).
- [2]全国第五次结核病流行病学抽样调查技术指导组,全国第五次结核病流行病学抽样调查办公室.2010年全国第五次结核病流行病学抽样调查报告[J].2012,(8).
- [3]段鸿飞,土井教生,李琦,等.鸟分枝杆菌复合群对16种抗感染药物药敏试验的分析[J].2010,(5).
- [4]全国结核病流行病学抽样调查技术指导组.第四次全国结核病流行病学抽样调查报告[J].2002,(1).
- [5]黄海荣,于霞,姜广路,等.利奈唑胺对分枝杆菌体外抑菌作用的初步研究[J].2011,(8).
- [6]Zuckerman JM,Qamar F,Bono BR.Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline).[J].2011,95(4).
- [7]Heifets Leonid B.,Lindholm-Levy Pamela J.,Comstock R. Dawn.Clarithromycin Minimal Inhibitory and Bactericidal Concentrations against Mycobacterium avium[J].1992.
- [8]Siedner M,Gilman RH,Grandjean L,etc.Inter- and intra-assay reproducibility of microplate Alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis.[J].2008,46(10).
- [9]Shin,S.J.,Woo,S.Y.,Jeong,B.-H.,etc.Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease[J].2012,142(6).
- [10]Wallace RJ Jr,Caccitolo J,Shepherd S,etc.Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.[J].2006,174(8).
- [11]S D, Shafran,J, Singer,D P, Zarowny,etc.A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.[J].1996,335.
- [12]Song,T.,Via,L.E.,Olivier,K.N.,etc.Linezolid for treatment of chronic extensively drug-resistant tuberculosis[J].2012,367(16).
- [13]Collins.Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.[J].1997,41.
- [14]McLaughlin JC,Quenzer VK,Ferguson RM,etc.Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.[J].1998,36(2).
- [15]Koh,W.-J.,Lee,S.-Y.,Jeong,B.-H.,etc.Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease[J].2012,186(8).
- [16]Totten,S.E.,Peloquin,C.A.,Daley,C.L.,etc.The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment[J].2012,186(6).